Cellectis Q1 Adj $(0.14) Beats $(0.33) Estimate, Sales $6.50M Beat $3.70M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellectis (NASDAQ:CLLS) reported better-than-expected Q1 results with an adjusted loss of $(0.14) per share, beating the $(0.33) estimate, and sales of $6.50 million, surpassing the $3.70 million estimate.
May 28, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis reported Q1 adjusted losses of $(0.14) per share, significantly beating the $(0.33) estimate. Sales also exceeded expectations at $6.50 million compared to the $3.70 million estimate.
The significant beat on both earnings and sales estimates is likely to positively impact Cellectis' stock price in the short term. The company's performance shows strong improvement over the same period last year, which should boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100